Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Alexion Pharmaceuticals ( ALXN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.2%. By the end of trading, Alexion Pharmaceuticals rose $1.59 (1.6%) to $98.19 on average volume. Throughout the day, 1,773,382 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1,935,700 shares. The stock ranged in a price between $96.70-$99.84 after having opened the day at $96.74 as compared to the previous trading day's close of $96.60. Other companies within the Health Care sector that increased today were: Vermillion ( VRML), up 30.1%, Affymax ( AFFY), up 25.7%, XOMA ( XOMA), up 22.4% and Cormedix ( CRMD), up 14.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $18.8 billion and is part of the drugs industry. The company has a P/E ratio of 66.0, above the S&P 500 P/E ratio of 17.7. Shares are up 2.8% year to date as of the close of trading on Wednesday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the negative front, MediciNova ( MNOV), down 26.8%, Orthofix International N.V ( OFIX), down 15.6%, Dendreon ( DNDN), down 15.0% and Transcept Pharmaceuticals ( TSPT), down 13.9% , were all laggards within the health care sector with Valeant Pharmaceuticals International ( VRX) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.
null

If you liked this article you might like

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

Stocks Get Boost From Stronger-Than-Expected Jobs Report

Stocks Get Boost From Stronger-Than-Expected Jobs Report

Stocks Higher After U.S. Adds More Jobs Than Expected in November

Stocks Higher After U.S. Adds More Jobs Than Expected in November

Alexion Spikes Amid Report Activist Elliott Management Is Pushing for Change

Alexion Spikes Amid Report Activist Elliott Management Is Pushing for Change

Stock Futures Add to Gains After Solid November Jobs Report

Stock Futures Add to Gains After Solid November Jobs Report